iiinova — where your digital self keeps evolving

WATCH: Benjamin Weinberg, MD, discusses how the @fda.gov approval of daraxonrasib for metastatic pancreatic adenocarcinoma might fuel future research in this disease. #pancsm #oncology Read more about the approval: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 15/10/2026

🎥 Megan Kruse, MD, of @clevelandclinic.bsky.social, discusses the potential utility of FES-PET/CT in lobular breast cancer for Global Lobular Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology Read on for more lobular disease insights ➡️: www.onclive.com/view/refined...

020 0

OncLive @onclive.bsky.social · 15/10/2026

In this episode of #OncologyUnplugged, Chandler Park, MD, and Jame Abraham, MD, discuss breast cancer management & the role of AI. @clevelandclinic.bsky.social #bcsm #oncology Watch on our site or listen on your favorite podcast platforms! www.onclive.com/view/biology...

010 0

OncLive @onclive.bsky.social · 15/10/2026

🗞️Just in: Following its August 2026 FDA approval, daraxonrasib has received a positive @ema.europa.eu CHMP opinion, recommending EU approval for patients with previously treated metastatic pancreatic adenocarcinoma #pancsm #oncology Read more: www.onclive.com/view/chmp-re...

110 0

OncLive @onclive.bsky.social · 14/10/2026

What data are set to move the needle in gynecologic oncology care during #ESMO26? Experts break down some of the top abstracts to watch in Madrid #gynsm #ovca #oncology Sign up and read more: www.onclive.com/view/long-te...

000 0

OncLive @onclive.bsky.social · 14/10/2026

The @fda.gov has accepted a resubmit BLA seeking the approval of tabelecleucel for the treatment adult and pediatric patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy #oncology Read more: www.onclive.com/view/fda-acc...

000 0

OncLive @onclive.bsky.social · 09/10/2026

At #ESMO26, GI oncology experts are keeping their eye on key presentations in CRC and pancreatic cancer. Sign up and read our preview of some of the top GI cancer abstracts to watch at the 2026 ESMO Congress in Madrid #crcsm #pancsm www.onclive.com/view/targete...

011 0

OncLive @onclive.bsky.social · 08/10/2026

🚨BREAKING: The @fda.gov has approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III dMMR colon cancer #crcsm #oncology Read more: www.onclive.com/view/fda-app...

110 0

OncLive @onclive.bsky.social · 08/10/2026

🚨BREAKING🚨: The @fda.gov has approved atezolizumab plus chemo for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair–deficient colon cancer. #crcsm #oncology Full story ➡️: www.onclive.com/view/fda-app...

010 0

OncLive @onclive.bsky.social · 08/10/2026

Following its May 2026 FDA approval, Dato-DXd has been approved in China for first-line metastatic TNBC ineligible for PD-1/PD-L1 inhibitor therapy #bcsm #oncology www.onclive.com/view/china-s...

010 0

OncLive @onclive.bsky.social · 07/10/2026

🚨 BREAKING 🚨: The @fda.gov approved maintenance tucatinib plus trastuzumab and pertuzumab for unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. #bcsm #oncology Full story ➡️: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 07/10/2026

What made the most noise at the 23rd IMS Annual Meeting? Peter Voorhees, MD; Gurbakhash Kaur, MD; C. Ola Landgren, MD, PhD; and Hans Lee, MD, break down the most important data and themes to emerge from #IMS26 Sign up and read more: www.onclive.com/view/etentam...

010 0

OncLive @onclive.bsky.social · 06/10/2026

WATCH 🎥: Alexis Ann LeVee, MD, previews the lidERA Breast Cancer PRO data being presented at the 2026 ESMO Congress. @myesmo.bsky.social #ESMO2026 #bcsm #oncology Sign up to read the full preview ➡️: www.onclive.com/view/breast-...

011 0

OncLive @onclive.bsky.social · 06/10/2026

WATCH 🎥: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, discusses key breast cancer abstracts being presented at the 2026 ESMO Congress. @myesmo.bsky.social #ESMO2026 #bcsm #oncology Sign up to read our preview article for more insights ➡️: www.onclive.com/view/breast-...

000 0

OncLive @onclive.bsky.social · 05/10/2026

📰 Just in: Epcoritamab plus R-CHOP improved PFS vs R-CHOP alone in newly diagnosed DLBCL, meeting the primary end point of the phase 3 EPCORE DLBCL-2 trial #lymsm #oncology Dive into the topline findings: www.onclive.com/view/epcorit...

000 0

OncLive @onclive.bsky.social · 05/10/2026

Treatment with PRV111, a cisplatin-releasing topical patch, led to a pCR rate of 95.5% in patients with noninvasive oral cancer or high-grade dysplasia in cohort 1 of the phase 2 portion of the ongoing CLN-004 trial #oncology Read more: www.onclive.com/view/cisplat...

000 0

OncLive @onclive.bsky.social · 02/10/2026

🚨BREAKING: The @fda.gov has approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion #leusm #oncology Read more: www.onclive.com/view/fda-app...

100 0

OncLive @onclive.bsky.social · 02/10/2026

🗞️ A @fda.gov NDA submission has been initiated for zipalertinib plus platinum-based chemotherapy in frontline, EGFR exon 20 insertion–positive NSCLC #lcsm #oncology Dive into the REZILIENT3 data supporting the application: www.onclive.com/view/nda-sub...

000 0

OncLive @onclive.bsky.social · 30/09/2026

👀 Looking ahead to the 2026 ESMO Congress? See which breast cancer presentations @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, and Alexis Ann LeVee, MD, are most looking forward to. @myesmo.bsky.social #bcsm #oncology Sign up to read the full preview ➡️: www.onclive.com/view/breast-...

000 0

OncLive @onclive.bsky.social · 29/09/2026

🗓️ What did August bring for GI oncology? From new FDA approvals in pancreatic and gastroesophageal cancers to regulatory actions across colorectal, rectal, and neuroendocrine tumors, here’s what to know: www.onclive.com/view/fda-fla...

010 0

OncLive @onclive.bsky.social · 23/09/2026

WATCH: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, highlights the @fda.gov approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, emergent ESR1-mutated breast cancer. #bcsm #oncology Read our coverage of the approval: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 21/09/2026

Ready for The Five Under 5 🕘? Here is your go-to roundup of the top 5 #OncLiveTV 📹 videos of last week. @danafarber.bsky.social @mdanderson.bsky.social @ucdavis.bsky.social #hematology #oncology Watch the clips that made the list 🔗: www.onclive.com/view/five-un...

000 0

OncLive @onclive.bsky.social · 18/09/2026

The EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology Read more: www.onclive.com/view/chmp-re...

000 0

OncLive @onclive.bsky.social · 18/09/2026

🇪🇺 @ema.europa.eu's CHMP recommended EU approval of adjuvant T-DXd monotherapy for patients with resected HER2+ breast cancer with residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy. #bcsm #oncology Full details ➡️: www.onclive.com/view/chmp-re...

000 0

OncLive @onclive.bsky.social · 17/09/2026

🎙️ On this #OncologyUnplugged episode, Chandler Park, MD, and Joshua Brody, MD, note evolving treatments for B-cell lymphomas. #lymsm #hematology Watch the episode on our site or listen on your favorite podcast platforms: www.onclive.com/view/fast-mo...

011 0

OncLive @onclive.bsky.social · 16/09/2026

📰 A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA. @stanfordmedicine.bsky.social #oncology See the full story here ➡️: www.onclive.com/view/europea...

000 0

OncLive @onclive.bsky.social · 16/09/2026

🏥Treatment of metastatic breast cancer is shifting in Japan. Today, the MHLW approved first-line T-DXd plus pertuzumab for HER2+ breast cancer, as well as first-line Dato-DXd for TNBC #bcsm #oncology www.onclive.com/view/japan-a...

010 0

OncLive @onclive.bsky.social · 16/09/2026

🗞️Just in: The FDA has granted fast track designation to the PD-1 x VEGF bispecific antibody cesalatamig for NSCLC after disease progression following concurrent or sequential PD-(L)1–targeted immunotherapy and platinum-based chemotherapy #lcsm #oncology www.onclive.com/view/fda-gra...

010 0

OncLive @onclive.bsky.social · 15/09/2026

🎙️ On this episode of #BreastCancerBriefing, Sara Nunnery, MD, and @matthewkurianmd.bsky.social discuss the role of AI in breast #oncology. @stelizabethnky.bsky.social #bcsm 👀 Watch the episode on our site or listen on your favorite podcast platform: www.onclive.com/view/oncolog...

010 0

OncLive @onclive.bsky.social · 15/09/2026

‼️ The @fda.gov has granted breakthrough therapy designation to daraxonrasib plus gemcitabine and nab-paclitaxel for treatment-naive mPDAC. #pancsm #oncology See our site for the full story ➡️: www.onclive.com/view/fda-gra...

110 0

OncLive @onclive.bsky.social · 14/09/2026

On this Two Onc Docs episode, Samantha A. Armstrong, MD, and @drkarinetawagi.bsky.social host a board-focused review of mNSCLC diagnosis and management. @uofillinois.bsky.social #lcsm #oncology Listen to the episode on our site or your favorite podcast platforms! www.onclive.com/view/non-sma...

011 0

OncLive @onclive.bsky.social · 11/09/2026

📈MPN expert, Andrew Kuykendall, MD, of Moffitt Cancer Center, ranked these headlining novel treatments in MPNs at #SOHO2026. ‼️Visit our site for more: www.onclive.com/conference/s... @societyofhemonc.bsky.social #mpnsm #oncology #hematology #cancer

000 0

OncLive @onclive.bsky.social · 11/09/2026

Although anselamimab missed the primary end point in the overall population, the agent plus anti-PCD improved all-cause mortality and CV-related hospitalization vs placebo in patients with newly diagnosed kappa AL amyloidosis #oncology Dive into the #SOHO2026 data: www.onclive.com/view/anselam...

000 0

OncLive @onclive.bsky.social · 10/09/2026

Treatment with DISC-3405 lowered the rates of phlebotomy after 26 weeks of treatment and maintained hematocrit levels below 45% in patients with polycythemia vera Dive into data from the phase 2 RESTORE-PV trial presented at #SOHO2026 www.onclive.com/view/disc-34...

000 0

OncLive @onclive.bsky.social · 09/09/2026

2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul! 🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷 @societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology

000 0

OncLive @onclive.bsky.social · 09/09/2026

🚨BREAKING: The @fda.gov has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced/metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations, as detected by an FDA-authorized test #lcsm #oncology www.onclive.com/view/fda-app...

010 0

OncLive @onclive.bsky.social · 09/09/2026

Initial results from the phase 2 SURF302 trial showed the oral FGFR3-selective inhibitor dabogratinib generated responses in patients with FGFR3-altered low-grade, intermediate-risk NMIBC #blcsm #oncology Read more: www.onclive.com/view/dabogra...

000 0

OncLive @onclive.bsky.social · 08/09/2026

On this episode of #BreastCancerBriefing, Sara Nunnery, MD, and Dana Bonaminio, MD, discuss the radiation oncologist's role in breast cancer screening. #bcsm #oncology Watch the video podcast on our site, or listen on your favorite podcast platforms! www.onclive.com/view/a-breas...

021 0

OncLive @onclive.bsky.social · 08/09/2026

Just in 📰: The GPRC5D-directed CAR T-cell therapy arlo-cel met the primary ORR end point of the phase 2 QUINTESSENTIAL trial in patients with quadruple-class exposed, relapsed/refractory multiple myeloma #mmsm #oncology Read more: www.onclive.com/view/arlo-ce...

010 0

OncLive @onclive.bsky.social · 04/09/2026

🚨BREAKING: The FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for the treatment of HR-positive, HER2-negative, advanced breast cancer that acquires an ESR1 mutation during AI and CDK4/6 inhibitor therapy. #bcsm #oncology Read more: www.onclive.com/view/fda-app...

100 0

OncLive @onclive.bsky.social · 03/09/2026

🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology Dive into the efficacy/safety highlights: www.onclive.com/view/etentam...

000 0

OncLive @onclive.bsky.social · 31/08/2026

An sNDA seeking the approval of selinexor in combination with ruxolitinib for the treatment of JAK inhibitor–naive myelofibrosis has been submitted to the @fda.gov #mpnsm #oncology Read more: www.onclive.com/view/fda-rec...

000 0

OncLive @onclive.bsky.social · 31/08/2026

🚨BREAKING: The @fda.gov has approved ropeginterferon alfa-2b for the treatment of adult patients with essential thrombocythemia #mpnsm #oncology Read more: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 27/08/2026

👀 Fangdi Sun, MD, discusses biomarkers in head and neck cancer. #oncology #headandneckcancer

001 0

OncLive @onclive.bsky.social · 26/08/2026

WATCH: Kim A. Reiss Binder, MD, of @pennmedicine.bsky.social, spotlights the mechanism of action of the @fda.gov-approved daraxonrasib for previously treated metastatic pancreatic adenocarcinoma. #pancsm #oncology Read the full approval story on our site ➡️: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 26/08/2026

🗞️Just in: First-line treatment with ivonescimab plus chemo yielded a statistically significant and clinically meaningful improvement in OS vs durvalumab plus chemo in advanced biliary tract cancer in the phase 3 HARMONi-GI1 trial #oncology #btcsm Read more: www.onclive.com/view/first-l...

010 0

OncLive @onclive.bsky.social · 25/08/2026

BREAKING🚨: The @fda.gov has approved zanidatamab-based combination regimens for the first-line treatment of patients with HER2-positive, unresectable locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma #oncology Read more: www.onclive.com/view/fda-app...

000 0

OncLive @onclive.bsky.social · 21/08/2026

The European Commission has approved teclistamab plus daratumumab for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy #mmsm #oncology Read more: www.onclive.com/view/europea...

000 0